Venmax Drugs & Pharmaceuticals Ratios

Venmax Drugs & Pharmaceuticals Ltd Ratios

The Venmax Drugs & Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Venmax Drugs & Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Venmax Drugs & Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Venmax Drugs & Pharmaceuticals Ltd (NSE: , BSE: 531015) is currently trading at ₹23.96, with a market capitalization of ₹0. As a major player in the Health technology sector and Pharmaceuticals: major industry, Venmax Drugs & Pharmaceuticals Ltd remains a key stock for fundamental analysis using Venmax Drugs & Pharmaceuticals Ltd Ratios.

Venmax Drugs & Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Venmax Drugs & Pharmaceuticals Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Venmax Drugs & Pharmaceuticals Ltd Ratios.

Historically, the Venmax Drugs & Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

The decline in Venmax Drugs & Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Venmax Drugs & Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

Venmax Drugs & Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Venmax Drugs & Pharmaceuticals Ltd P/S ratio currently stands at 0, an important part of Venmax Drugs & Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

A stable or declining Venmax Drugs & Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.

Venmax Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Venmax Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Venmax Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio:

The declining Venmax Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Venmax Drugs & Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Venmax Drugs & Pharmaceuticals Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

Venmax Drugs & Pharmaceuticals Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Venmax Drugs & Pharmaceuticals Ltd EV/EBITDA ratio is currently 0, a key metric in Venmax Drugs & Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

Stable Venmax Drugs & Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.

Venmax Drugs & Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Venmax Drugs & Pharmaceuticals Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

Venmax Drugs & Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Venmax Drugs & Pharmaceuticals Ltd ROE currently stands at 0%, showing profitability and capital efficiency.

Historical ROE:

Declining ROE indicates pressure on profitability.

Venmax Drugs & Pharmaceuticals Ltd Ratios Analysis Summary

The Venmax Drugs & Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Venmax Drugs & Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Venmax Drugs & Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.